Identification of a nanobody able to catalyze the destruction of the spike-trimer of SARS-CoV-2.

IF 3.9 3区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Frontiers of Medicine Pub Date : 2025-06-01 Epub Date: 2025-05-03 DOI:10.1007/s11684-025-1128-4
Kai Wang, Duanfang Cao, Lanlan Liu, Xiaoyi Fan, Yihuan Lin, Wenting He, Yunze Zhai, Pingyong Xu, Xiyun Yan, Haikun Wang, Xinzheng Zhang, Pengyuan Yang
{"title":"Identification of a nanobody able to catalyze the destruction of the spike-trimer of SARS-CoV-2.","authors":"Kai Wang, Duanfang Cao, Lanlan Liu, Xiaoyi Fan, Yihuan Lin, Wenting He, Yunze Zhai, Pingyong Xu, Xiyun Yan, Haikun Wang, Xinzheng Zhang, Pengyuan Yang","doi":"10.1007/s11684-025-1128-4","DOIUrl":null,"url":null,"abstract":"<p><p>Neutralizing antibodies have been designed to specifically target and bind to the receptor binding domain (RBD) of spike (S) protein to block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus from attaching to angiotensin converting enzyme 2 (ACE2). This study reports a distinctive nanobody, designated as VHH21, that directly catalyzes the S-trimer into an irreversible transition state through postfusion conformational changes. Derived from camels immunized with multiple antigens, a set of nanobodies with high affinity for the S1 protein displays abilities to neutralize pseudovirion infections with a broad resistance to variants of concern of SARS-CoV-2, including SARS-CoV and BatRaTG13. Importantly, a super-resolution screening and analysis platform based on visual fluorescence probes was designed and applied to monitor single proteins and protein subunits. A spontaneously occurring dimeric form of VHH21 was obtained to rapidly destroy the S-trimer. Structural analysis via cryogenic electron microscopy revealed that VHH21 targets specific conserved epitopes on the S protein, distinct from the ACE2 binding site on the RBD, which destabilizes the fusion process. This research highlights the potential of VHH21 as an abzyme-like nanobody (nanoabzyme) possessing broad-spectrum binding capabilities and highly effective anti-viral properties and offers a promising strategy for combating coronavirus outbreaks.</p>","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":" ","pages":"493-506"},"PeriodicalIF":3.9000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers of Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11684-025-1128-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Neutralizing antibodies have been designed to specifically target and bind to the receptor binding domain (RBD) of spike (S) protein to block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus from attaching to angiotensin converting enzyme 2 (ACE2). This study reports a distinctive nanobody, designated as VHH21, that directly catalyzes the S-trimer into an irreversible transition state through postfusion conformational changes. Derived from camels immunized with multiple antigens, a set of nanobodies with high affinity for the S1 protein displays abilities to neutralize pseudovirion infections with a broad resistance to variants of concern of SARS-CoV-2, including SARS-CoV and BatRaTG13. Importantly, a super-resolution screening and analysis platform based on visual fluorescence probes was designed and applied to monitor single proteins and protein subunits. A spontaneously occurring dimeric form of VHH21 was obtained to rapidly destroy the S-trimer. Structural analysis via cryogenic electron microscopy revealed that VHH21 targets specific conserved epitopes on the S protein, distinct from the ACE2 binding site on the RBD, which destabilizes the fusion process. This research highlights the potential of VHH21 as an abzyme-like nanobody (nanoabzyme) possessing broad-spectrum binding capabilities and highly effective anti-viral properties and offers a promising strategy for combating coronavirus outbreaks.

一种能够催化SARS-CoV-2刺状三聚体破坏的纳米体的鉴定。
中和抗体已被设计用于特异性靶向并结合刺突(S)蛋白受体结合域(RBD),以阻止严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)病毒附着在血管紧张素转换酶2 (ACE2)上。本研究报道了一种独特的纳米体,命名为VHH21,通过融合后构象变化直接催化s -三聚体进入不可逆过渡态。来自经多种抗原免疫的骆驼的一组对S1蛋白具有高亲和力的纳米体显示出了中和假病毒粒子感染的能力,并对SARS-CoV-2关注的变体(包括SARS-CoV和BatRaTG13)具有广泛的抗性。重要的是,设计了一个基于视觉荧光探针的超分辨率筛选和分析平台,并将其用于监测单个蛋白质和蛋白质亚基。获得了一种自发形成的二聚体形式的VHH21,以快速破坏s -三聚体。低温电镜结构分析显示,VHH21靶向S蛋白上的特定保守表位,与RBD上的ACE2结合位点不同,这使得融合过程不稳定。该研究强调了VHH21作为一种具有广谱结合能力和高效抗病毒特性的类酶纳米体(纳米酶)的潜力,为抗击冠状病毒爆发提供了一种有希望的策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Frontiers of Medicine
Frontiers of Medicine ONCOLOGYMEDICINE, RESEARCH & EXPERIMENTAL&-MEDICINE, RESEARCH & EXPERIMENTAL
CiteScore
18.30
自引率
0.00%
发文量
800
期刊介绍: Frontiers of Medicine is an international general medical journal sponsored by the Ministry of Education of China. The journal is jointly published by the Higher Education Press and Springer. Since the first issue of 2010, this journal has been indexed in PubMed/MEDLINE. Frontiers of Medicine is dedicated to publishing original research and review articles on the latest advances in clinical and basic medicine with a focus on epidemiology, traditional Chinese medicine, translational research, healthcare, public health and health policies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信